Fish Oil Supplementation, Resting Energy Expenditure, Skeletal Muscle Membrane Composition and Metabolism in Elderly Subjects.

NCT ID: NCT02338401

Last Updated: 2017-05-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2017-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Resting metabolic rate (RMR) declines by 1-2% per decade after 20 years of age. This reduction is linked to a decrease in fat free mass (FFM) (10-20%) and the rate of energy expenditure of tissues (Manini 2010).

It has also been shown that as we age there is a:

* Concomitant reduction in basal fat and carbohydrate oxidation, most likely due to the decrease in RMR than to a change in respiratory exchange ratio (RER) (St-Onge and Gallagher 2010).
* A change towards a more saturated membrane of different tissues (Rabini et al 2002).

Incorporation of omega-3s, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), into cell membranes may alter energy metabolism by:

* Increasing the rate at which proteins operate (Hulbert 2007).
* Promoting the release of EPA and DHA into the cytosol which will act as ligands for peroxisome proliferator-activated receptors (PPARs) (Calder 2011). PPARs play an important role in energy homeostasis by regulating genes involved in lipid metabolism (Kota et al 2005).
* Augmenting protein synthesis through activation of the mTOR-p70s6k pathway (Di Girolamo et al 2014).

Supplementation with fish oil in older males and females:

* Increases whole muscle phospholipid profile of EPA and DHA (Smith et al 2011).
* Increases lean body mass (LBM), RMR, and fatty acid oxidation (Logan et al unpublished)
* Decreases carbohydrate oxidation (Logan et al unplubished). Skeletal muscle (SM) accounts for 20-30% of RMR (Zurlo et al 1990, Manini 2010), therefore it is tempting to speculate that these changes may occur by some of the mechanisms described earlier, with skeletal muscle being an important contributor.

To date there are no studies that have examined the effect of n-3 supplementation (3g/day)\* on plasma membrane fatty acid composition, RMR and substrate oxidation, and the possible mechanisms behind it.

Therefore the purpose of this study is to determine whether in older adults (female and male), supplementation with n-3 alters:

1. RMR and fatty acid oxidation.
2. Membrane composition of whole muscle and sarcolemma.
3. Content of skeletal muscle membrane fatty acid transport proteins.
4. Dose response of NaKATPase and SERCA efficiency
5. Content of mitochondrial proteins
6. Expression and content of PPARs and proteins involved in translocation of FA transporters (AMPK, ERK1/2, CamKII).
7. Phosphorylation of AMPKα(THR172), ERK1/2(THR202 TYR204) and CaMKII(THR286).
8. Proteomic profile of skeletal muscle.
9. Body composition

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Whole Body and Skeletal Muscle Energy Metabolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Omega-3 Complete

Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.

Group Type EXPERIMENTAL

Omega-3 Complete

Intervention Type DIETARY_SUPPLEMENT

Fish Oil Capsules

Placebo Pill

Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.

Group Type PLACEBO_COMPARATOR

Placebo Pill

Intervention Type DIETARY_SUPPLEMENT

Olive Oil Capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omega-3 Complete

Fish Oil Capsules

Intervention Type DIETARY_SUPPLEMENT

Placebo Pill

Olive Oil Capsules

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between 60 and 75 years old
* Must currently practice a consistent diet and exercise regimen, and maintain this throughout the duration of the study

Exclusion Criteria

* Have any medical condition (no evidence of significant cardiovascular disease or organ dysfunction, including hypertension, dyslipidemia, and diabetes mellitus), and hospitalization or surgeries
* Consume more than two meals of fish/wk and/or have taken an omega-3 supplement during the prior three months.
* Have a BMI \> 30 kg/m2
Minimum Eligible Age

60 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Guelph

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lawrence Spriet

Professor and Chair Human Health and Nutritional Sciences

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Guelph

Guelph, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

University of Guelph

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Omega-3 Fatty Acids to Combat Sarcopenia
NCT02103842 COMPLETED PHASE1
Fish Oil and Muscle Function
NCT01308957 COMPLETED NA
Enhancing Adaptations to Exercise
NCT03350906 COMPLETED PHASE3